Future pharmacological approaches aimed at compensating altered GABAergic function or restoring dystrophin function in mdx mice might be helpful to further delineate the physiopathology of autistic traits in DMD, to highlight the importance of the neuroligin and neurexin complex in ASD and to unveil new leads to alleviate behavioral symptoms in DMD patients. This evidence concerns the gene DMD and Duchenne muscular dystrophy.